New drug combo aims to boost surgery success in colon cancer
NCT ID NCT07677579
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial is testing whether giving two drugs—Zanzalintinib and Retifanlimab—before surgery can help patients with early-stage colon cancer. The study enrolls adults aged 18 to 80 with a type of colon cancer called pMMR that can be removed surgically. Participants receive the drug combination for six weeks, then undergo surgery within 14 to 35 days. The main goal is to see how many patients can proceed to surgery as planned, while also checking for side effects and signs that the tumor has shrunk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Zanzalintinib and Retifanlimab
What this could lead to
If successful, this approach could make surgery more effective and reduce the chance of cancer returning in patients with early-stage colon cancer.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. The combination therapy may cause side effects or fail to improve outcomes compared to standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••